Control Bionics (ASX:CBL)

Thanks to Stockhead TV for this valuable roundup of our key 2024 achievements and what we're aiming for in 2025. As we continue to diversify our offerings and unlock new opportunities, we’re excited about what’s ahead for Control Bionics in 2025. Jeremy Steele Joe Durak Lindsay Phillips David Falk Kanak Sahasrabudhe Adi Deshpande

Moira's mom, Dania Ermentrout, tells us, "With her device's AI capabilities in ChatCrackers, Moira's creativity knows no bounds." Check out the full blog post here: https://lnkd.in/g-G4aZvn

Control Bionics (ASX:CBL) is launching our partnership with NeuroBounce in Australia in 2025. We'd like to hear from individuals with an exercise science degree or significant training and experience as a strength and conditioning coach. The role will initially be flexible part-time commencing later this month for a 3 month period. The person will need to be Melbourne based. The role will receive training and support on the world class jump program from the US. Further information and how to apply is in the attached document. This is a fantastic opportunity to launch a program that delivers extraordinary results for athletes.

It's not too late to register!! Use the link below!!

We are partnering with Numotion Speech Solutions to provide a free webinar with possible CEU credit on January 7th. Use the information below to register and join us to learn more about Scanning with the NeuroNode Trilogy!

Join us today for our Investor Briefing to hear more about our business update and recent agreements for further global expansion. Register: https://bit.ly/3Bts4rt

📢 First Half FY25 Business Update – Strong Growth in the U.S. Control Bionics (ASX:CBL) is pleased to share an update on our performance for the first half of FY25, driven by strong revenue growth and ongoing expansion efforts. Key highlights: ✅ U.S. Revenue Growth: Anticipated to exceed 15% YoY for 1H FY25, with H2 calendar 2024 expected to grow nearly 30% compared to H1. ✅ Australian Revenue Momentum: Revenue in the second half of calendar 2024 is projected to grow by over 20% compared to the first half, demonstrating resilience and effective sales strategies. ✅ NeuroNode Only Sales: Enabled by our new HCPCS code, bolstering market penetration. ✅ DROVE Progress: Four demonstration sites operational in Australia and our first distribution partnership with Motion Specialities in Queensland. Initial NDIS funding applications are underway. ✅ FDA Partnership: Finalising clinical trial collaboration with Cleveland Metro Health for DROVE’s FDA approval, targeting submission by mid-2025. ✅ Cost Optimisation: A$700k in annualised savings from strategic U.S. cost reductions to enhance profitability. We’re excited to build on this momentum as we continue to diversify into new markets and deliver transformative solutions in assistive communication and mobility. Join us for our investor briefing on 17 December for more details! #ControlBionics #NeuroNode #DROVE #AssistiveTechnology #Innovation #ASX Joe Durak Jeremy Steele Roger Hawke David Falk Lindsay Phillips Peter S Ford Kanak Sahasrabudhe Kerry Series Thomas Conn

Control Bionics leaps into new US and Japanese markets with strategic deals https://buff.ly/49LHS5C #ASX #ASX200 $CBL Control Bionics (ASX:CBL)

🌟 Major Milestone: We're expanding into U.S. Sports and Japanese Rehabilitation Markets with our first commercial agreements for NeuroStrip® technology —two high-growth global markets. Key highlights include: ✅ Strategic investment in Neuro Elite Athletics, accelerating the rollout of the NeuroBounce program in the U.S., which delivers outstanding results in vertical leap and athletic performance using. ✅ Agreement with Stroke Lab, a premier Japanese rehabilitation facility, to localise NeuroStrip® for stroke and neurological therapy. This agreement establishes a framework for a joint operating agreement by Q1 2025. ✅  New recurring revenue streams from SaaS and hardware sales, while leveraging exclusive access to anonymised patient and athlete data for future AI model development. ✅ Australian and Japanese Expansion: Exclusive rights to market NeuroBounce in Australia and Japan, leveraging long-standing IP for new markets. Our CEO Jeremy Steele says “These collaborations underscore Control Bionics’ ability to enter and lead high-growth markets. With NeuroBounce’s proven success in sports and Stroke Lab’s rehabilitation expertise, we are driving innovation while delivering value for our shareholders.” Mr Steele went on to say “By strengthening our relationships with existing customers, it offers us the opportunity to more rapidly scale Control Bionics. In addition, delivering on our objective of diversifying into new markets and generating recurring revenue we are building a business that has a very promising future.” These agreements are with existing customers and validate the global potential of NeuroStrip® technology, opening up opportunities in sports science, health diagnostics, and beyond, as Control Bionics diversifies into new markets while building on trusted customer relationships. #NeuroStrip #ControlBionics #Innovation #SportsPerformance #Rehabilitation #HealthTech #ASX Jeremy Steele Roger Hawke Damian Lismore Joe Durak Kanak Sahasrabudhe Kerry Series David Falk Lindsay Phillips Thomas Conn